International trends in the incidence of testicular cancer, 1973-2002.
BACKGROUND
Whereas testicular cancer incidence rates have been widely reported in populations of Northern European ancestry, rates in other populations have been less frequently examined. In a prior report, global testicular cancer incidence rates and trends for the years 1973 to 1997 were summarized. The current report extends these analyses with an additional 5 years of data from Cancer Incidence in Five Continents.


METHODS
Age-standardized incidence rates over successive 5-year time periods were obtained for populations in the Americas, Asia, Europe, and Oceania.


RESULTS
In general, testicular cancer incidence remained highest in Northern European populations (8.0-9.0 per 100,000) and lowest in Asian and African populations (<1 per 100,000). One notable exception to this pattern, however, was the very high rate reported by the Valdivia, Chile registry (8.8 per 100,000). In many populations, rates rose between 1973 and 2002, although the increases were strongest and most consistent among populations of European ancestry. In certain European populations, such as those of Denmark and of Geneva, Switzerland, some recent plateauing of rates was evident. There was little evidence of increase and possible evidence of a modest decline in rates among east Asian populations. Trends by histology (seminoma and nonseminoma) were generally similar to one another.


CONCLUSIONS
Risk of testicular cancer remains relatively high in Northern European populations and low in Asian and African populations. Similar trends by histology suggest common risk factors. EFFECT: Reasons for increasing rates among Northern Europeans and stable or declining rates among East Asians are unexplained, supporting the need for future etiologic studies.
Chia
Victoria M
VM
Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, EPS/Suite 550, 6120 Executive Boulevard, Rockville, MD 20892-7234, USA.
Quraishi
Sabah M
SM
Devesa
Susan S
SS
Purdue
Mark P
MP
Cook
Michael B
MB
McGlynn
Katherine A
KA
D014943:Global Health; D006801:Humans; D015994:Incidence; D008297:Male; D013736:Testicular Neoplasms / Q000453:epidemiology*
Cancer Causes Control. 1992 May;3(3):265-72
1610973
J Urol. 2007 Jul;178(1):125-8
17499277
Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):652-8
16614105
Int J Cancer. 1995 Jun 9;61(6):761-4
7790108
Int J Androl. 2009 Aug;32(4):306-16
18179558
Cancer Causes Control. 1998 May;9(3):253-8
9684705
Cancer Causes Control. 2008 Dec;19(10):1043-9
18478339
Int J Cancer. 2004 May 10;109(6):941-4
15027129
Int J Cancer. 1988 Mar 15;41(3):399-403
2831159
BMJ. 1994 May 28;308(6941):1393-9
7912596
Int J Cancer. 1999 Nov 26;83(5):630-4
10521799
Am J Epidemiol. 1986 Jul;124(1):39-52
2872797
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1820-4
17035387
Nat Rev Cancer. 2005 Mar;5(3):210-22
15738984
Int J Cancer. 2004 Apr 10;109(3):425-9
14961582
Int J Cancer. 2005 Jul 10;115(5):822-7
15704170
J Natl Cancer Inst. 2008 May 7;100(9):663-71
18445826
Int J Cancer. 2007 May 1;120(9):2044-6
17278105
APMIS. 2008 Sep;116(9):816-22
19024602
Br J Cancer. 1999 Aug;80(11):1859-63
10468310
J Occup Environ Med. 1997 Apr;39(4):333-8
9113604
Environ Health Perspect. 2003 Jun;111(7):930-4
12782494
Nat Clin Pract Urol. 2006 Oct;3(10):532-43
17031378
Int J Oncol. 1998 Dec;13(6):1299-303
9824648
Int J Androl. 2006 Feb;29(1):199-204
16371112
Lancet. 1993 May 29;341(8857):1392-5
8098802
J Urol. 1988 Feb;139(2):308-10
2828695
Cancer Res. 2009 Mar 1;69(5):1901-9
19223531
Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2157-66
15598775
Int J Cancer. 2002 May 10;99(2):229-37
11979438
Int J Cancer. 1999 Jul 2;82(1):1-5
10360811
Int J Cancer. 2002 May 10;99(2):218-28
11979437
PLoS One. 2008;3(10):e3519
18949038
APMIS. 1998 Jan;106(1):198-204; discussion 204-6
9524579
Int J Epidemiol. 2000 Oct;29(5):826-31
11034964
Br J Cancer. 1999 Jun;80(7):1098-102
10362123
J Natl Cancer Inst. 1996 Jun 5;88(11):727-33
8637026
Br J Cancer. 1984 Sep;50(3):377-80
6466547
J Pathol. 2004 Jul;203(3):849-57
15221945
Int J Cancer. 2010 Jan 1;126(1):217-23
19588505
CMAJ. 1999 Jan 26;160(2):201-5
9951441
Int J Cancer. 1998 Oct 5;78(2):140-3
9754641
Cancer Epidemiol Biomarkers Prev. 1996 Jan;5(1):3-9
8770459
Int J Androl. 2006 Feb;29(1):228-34
16371110
Cancer Causes Control. 1997 Nov;8(6):904-12
9427433
Cancer Causes Control. 2006 Sep;17(7):983-7
16841265
J Urol. 2003 Jul;170(1):5-11
12796635
Ugeskr Laeger. 1997 Nov 10;159(46):6815-9
9411993
Br J Ind Med. 1988 Apr;45(4):225-30
3377998
Int J Androl. 2004 Oct;27(5):282-90
15379968
Eur J Cancer Prev. 2003 Aug;12(4):347-9
12883390
Eur J Cancer. 1995 Nov;31A(12):2044-8
8562163
APMIS. 1998 Jan;106(1):225-9; discussion 229-31
9524583
Int J Androl. 2007 Aug;30(4):206-13; discussion 213-4
17708751
J Cancer Res Clin Oncol. 2009 May;135(5):731-8
19002497
Am J Epidemiol. 2007 Feb 15;165(4):355-63
17110638
Cancer. 2003 Jan 1;97(1):63-70
12491506
APMIS. 1994 Jan;102(1):38-42
8166998
Am J Epidemiol. 1995 Feb 15;141(4):300-4
7840107
Cancer. 2009 Mar 15;115(6):1215-23
19204904
Cancer Causes Control. 2008 Mar;19(2):155-61
18236173
Int J Cancer. 2000 Aug 1;87(3):438-43
10897052
Eur Urol. 1993;24(2):271-6
8397088
Stat Med. 2003 Sep 15;22(17):2751-66
12939784